Tandem Diabetes Care Announces Closing of $115 Million Underwritten Public Offering of Common Stock
08 August 2018 - 6:05AM
Business Wire
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), (“Tandem”) a medical
device company and manufacturer of the only touchscreen insulin
pumps available in the United States, today announced the closing
of its previously announced underwritten public offering of
3,508,770 shares of common stock at a price to the public of $28.50
per share. In addition, the underwriters fully exercised an option
to purchase 526,315 additional shares of common stock at the public
offering price. All of the shares in the offering were offered by
Tandem, with gross proceeds to Tandem of approximately $115
million.
Oppenheimer & Co. Inc. acted as the sole book‐running
manager for the offering. Robert W. Baird & Co. Incorporated
acted as a co-manager in connection with the offering.
A shelf registration statement on Form S-3 relating to these
securities was filed by Tandem with the Securities and Exchange
Commission and declared effective on May 9, 2018. A copy of the
final prospectus supplement and accompanying prospectus relating to
and describing the terms of the offering may be obtained from:
Oppenheimer & Co. Inc. Attention: Syndicate Prospectus
Department, 85 Broad St., 26th Floor, New York, NY 10004, by
telephone at (212) 667-8055 or by email at
EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company dedicated to improving the lives of people with
diabetes through relentless innovation and revolutionary customer
experience. Tandem takes an innovative, user-centric approach to
the design, development and commercialization of products for
people with diabetes who use insulin. Tandem manufactures and sells
the t:slim X2™ Insulin Pump with Basal-IQ™ technology. The t:slim
X2 Pump is capable of remote feature updates using a personal
computer, and is the first insulin pump designated as compatible
with integrated continuous glucose monitoring (iCGM) devices.
Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark, and t:slim X2
and Basal-IQ are trademarks of Tandem Diabetes Care, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180807005852/en/
Tandem Diabetes Care, Inc.Media Contact:Steve Sabicer,
714-907-6264ssabicer@thesabicergroup.comorInvestor
Contact:Susan Morrison, 858-366-6900
x7005smorrison@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Apr 2024 to May 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From May 2023 to May 2024